NASDAQ:NRSN NeuroSense Therapeutics (NRSN) Stock Price, News & Analysis → Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad) Free NRSN Stock Alerts $1.21 -0.01 (-0.82%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$1.16▼$1.2950-Day Range$1.12▼$2.0652-Week Range$0.40▼$2.33Volume79,991 shsAverage Volume108,019 shsMarket Capitalization$16.54 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get NeuroSense Therapeutics alerts: Email Address Ad Paradigm PressForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.Click here to find out that this 8,788% cryptocurrency is. About NeuroSense Therapeutics Stock (NASDAQ:NRSN)NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.Read More NRSN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NRSN Stock News HeadlinesMay 14, 2024 | prnewswire.comNeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine LearningMay 7, 2024 | markets.businessinsider.comNeuroSense Reports Positive Data Analysis From PARADIGM Trial With PrimeC In ALSMay 7, 2024 | prnewswire.comNeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS PatientsMay 2, 2024 | prnewswire.comNeuroSense Announces First Quarter 2024 Business UpdateApril 22, 2024 | finance.yahoo.comNeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's DiseaseApril 19, 2024 | investing.comNeuroSense reports positive ALS trial results, trends in biomarkersApril 18, 2024 | prnewswire.comNeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual MeetingApril 12, 2024 | finance.yahoo.comNeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024April 12, 2024 | prnewswire.comNeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024April 10, 2024 | prnewswire.comNeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private PlacementApril 9, 2024 | markets.businessinsider.comNeuroSense Joins With Lonza To Advance Neurodegenerative Disease Treatments; Stock Up In Pre-marketApril 9, 2024 | prnewswire.comNeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and DiagnosticsApril 7, 2024 | uk.investing.comNeuroSense reports significant ALS trial results, year-end financialsApril 5, 2024 | investorplace.comNRSN Stock Earnings: NeuroSense Therapeutics Beats EPS for Q4 2023April 5, 2024 | finance.yahoo.comNeuroSense Announces Year End 2023 Financial Results and Provides Business UpdateMarch 23, 2024 | morningstar.comNeuroSense Therapeutics Ltd NRSNFebruary 21, 2024 | finance.yahoo.comNeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM TrialFebruary 21, 2024 | prnewswire.comNeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM TrialFebruary 7, 2024 | finance.yahoo.comNeuroSense Regains Compliance with NASDAQ Minimum Bid Price RuleJanuary 30, 2024 | finanznachrichten.deNeuroSense Therapeutics Ltd: NeuroSense's ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024January 30, 2024 | finance.yahoo.comNeuroSense’s (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024January 9, 2024 | finance.yahoo.comNeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 CatalystsJanuary 4, 2024 | finance.yahoo.comNeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity RequirementDecember 19, 2023 | investing.comNeurosense Therapeutics (NRSN) Earnings Dates & ReportsDecember 16, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and Neurosense Therapeutics Ltd. (NRSN)See More Headlines Receive NRSN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuroSense Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/05/2024Today5/19/2024Next Earnings (Estimated)6/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NRSN CUSIPN/A CIK1875091 Webwww.neurosense-tx.com Phone972-9799-6183FaxN/AEmployees18Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,280,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-678.59% Return on Assets-207.30% Debt Debt-to-Equity RatioN/A Current Ratio0.84 Quick Ratio0.84 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.14) per share Price / Book-8.64Miscellaneous Outstanding Shares13,670,000Free Float9,922,000Market Cap$16.54 million OptionableNot Optionable Beta1.73 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Or Eisenberg (Age 43)Chief Financial Officer Comp: $382kDr. Ferenc Tracik M.D. (Age 60)Chief Medical Officer Comp: $532kMr. Alon Ben-Noon (Age 45)Co-Founder, CEO & Director Comp: $619kMs. Hagit Binder (Age 46)Chief Operation Officer Dr. Niva Russek-Blum Ph.D. (Age 45)Chief Technology Officer Ms. Yael Barak (Age 54)VP of Quality & Compliance Ms. Keren PushettHead of HRMr. Eidan LoushiC.R.A.More ExecutivesKey CompetitorsTonix PharmaceuticalsNASDAQ:TNXPEdesa BiotechNASDAQ:EDSAVincerx PharmaNASDAQ:VINCFlora GrowthNASDAQ:FLGCTraws PharmaNASDAQ:TRAWView All Competitors NRSN Stock Analysis - Frequently Asked Questions Should I buy or sell NeuroSense Therapeutics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeuroSense Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" NRSN shares. View NRSN analyst ratings or view top-rated stocks. How have NRSN shares performed in 2024? NeuroSense Therapeutics' stock was trading at $0.7850 at the beginning of the year. Since then, NRSN shares have increased by 54.1% and is now trading at $1.21. View the best growth stocks for 2024 here. When is NeuroSense Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, June 6th 2024. View our NRSN earnings forecast. How were NeuroSense Therapeutics' earnings last quarter? NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) announced its quarterly earnings results on Friday, April, 5th. The company reported ($0.16) EPS for the quarter. When did NeuroSense Therapeutics IPO? NeuroSense Therapeutics (NRSN) raised $13 million in an IPO on Thursday, December 9th 2021. The company issued 2,000,000 shares at $6.00-$7.00 per share. How do I buy shares of NeuroSense Therapeutics? Shares of NRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NRSN) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingShocking $16T Elon Musk Crypto LeakCrypto 101 MediaForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsDems have chosen Biden replacement?Paradigm PressHow Biden has already won 2024Porter & CompanyExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersA letter is coming from the "Bureau of the Fiscal Service".Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroSense Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.